ArticleERJ open research2023

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf.

James D Chalmers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.